Mirati Therapeutics Inc MRTX

NAS: MRTX | ISIN: US60468T1051   22/01/2024
58,70 USD (-0,17%)
(-0,17%)   22/01/2024

10 januari 2024 · European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation · Persbericht

10 november 2023 · Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure · Persbericht

6 november 2023 · Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates · Persbericht

3 november 2023 · Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation · Persbericht

31 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, PCTI, MRTX · Persbericht

26 oktober 2023 · Moore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law Firm · Persbericht

17 oktober 2023 · Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC) · Persbericht

17 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNSL, PCTI, SP, MRTX · Persbericht

10 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWLI, MRTX, SLGC, PNT · Persbericht

9 oktober 2023 · Shareholder Alert: Ademi LLP investigates whether Mirati Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myers Squibb · Persbericht

27 september 2023 · Mirati To Present Updated Clinical Data at ESMO Congress 2023 · Persbericht

10 september 2023 · Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer · Persbericht

5 september 2023 · Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

29 augustus 2023 · Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference · Persbericht

23 augustus 2023 · Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer · Persbericht

21 augustus 2023 · Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer · Persbericht

11 augustus 2023 · Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

9 augustus 2023 · Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition · Persbericht

9 augustus 2023 · Mirati Therapeutics Announces Pricing of Upsized Public Offering · Persbericht

8 augustus 2023 · Mirati Therapeutics Announces Proposed Public Offering · Persbericht

Mijn selecties